Business, energy, technology, markets and global industry news from Business News Today

Swedish Orphan Biovitrum

PharmaDeviceNews Swedish Orphan Biovitrum
Editorial infographic highlighting Innate Pharma’s November 5, 2026 update, featuring a clinical research laboratory, immunotherapy imagery, a calendar, and key developments involving IPH4502, the Sobi partnership and monalizumab.
Pharma & Biotech

Innate Pharma faces a crucial November update. Can its ADC pipeline and Sobi deal strengthen its position?

Innate Pharma plans its November 5 update as IPH4502 data, the Sobi partnership and monalizumab milestones approach. Key clinical questions remain.

Read More
Innate Pharma’s lacutamab partnership with Sobi could unlock the TELLOMAK-3 Phase 3 trial and a potential accelerated approval pathway in T-cell lymphoma, with the licensing agreement carrying up to $580 million in potential value. Representative image.
Pharma & Biotech

What Sobi’s lacutamab licensing deal means for Innate Pharma and TELLOMAK-3

Innate Pharma’s Sobi deal brings $75m upfront and could unlock TELLOMAK-3, accelerated approval and global commercialization of lacutamab.

Read More
Sobi to acquire Arthrosi in $950m deal ahead of pivotal Phase 3 gout data.
Pharma & Biotech

Sobi bets $950m on Arthrosi to reshape chronic gout treatment with pozdeutinurad

Swedish Orphan Biovitrum AB (Sobi) has entered into a definitive agreement to acquire Arthrosi Therapeutics Inc. for $950 million upfront and up to $550 million in milestone payments. The deal brings the investigational gout drug pozdeutinurad (AR882) into Sobi’s pipeline, positioning the oral URAT1 inhibitor as a potential anchor asset in a late-stage inflammatory franchise.

Read More